RU58642

RU-58642

RU-58642

Chemical compound

RU-58642 is a nonsteroidal antiandrogen (NSAA) derived from nilutamide with very high affinity and selectivity for the androgen receptor (AR), which made it among the most potent and efficacious antiandrogens known at the time of its discovery.[1] It was investigated for topical application for the treatment of androgenetic alopecia (male-pattern baldness), but development did not proceed past initial trial stages, and it is now only used for scientific research into the AR.[2][3]

Quick Facts Clinical data, Drug class ...

See also

References

  1. [1]
    Battmann T, Branche C, Bouchoux F, Cerede E, Philibert D, Goubet F, Teutsch G, Gaillard-Kelly M (January 1998). "Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders". The Journal of Steroid Biochemistry and Molecular Biology. 64 (1–2): 103–11. doi:10.1016/S0960-0760(97)00151-9. PMID 9569015. S2CID 290926.
  2. [2]
    Sims NA, Clément-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, Resche-Rigon M, Baron R (May 2003). "A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice". The Journal of Clinical Investigation. 111 (9): 1319–27. doi:10.1172/JCI17246. PMC 154447. PMID 12727923.
  3. [3]
    Windahl SH, Galien R, Chiusaroli R, Clément-Lacroix P, Morvan F, Lepescheux L, Nique F, Horne WC, Resche-Rigon M, Baron R (September 2006). "Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor". The Journal of Clinical Investigation. 116 (9): 2500–9. doi:10.1172/JCI28809. PMC 1555662. PMID 16955145.



Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Stub icon

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article RU58642, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.